NTHI

Business Context and Reporting Period

Company: NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: A clinical-stage biopharmaceutical company developing novel drug delivery methods for intracranial malignancies. The lead product, NEO100 (intranasal delivery for glioblastoma), holds Orphan Drug and Fast Track designations. The company listed on the Nasdaq Global Market on March 26, 2025.

Key Financial Metrics

Debt and Liquidity: The company holds convertible promissory notes of approximately $4.7 million (net of discount). Cash flow from financing activities provided $18.2 million for the nine months ended September 30, 2025, primarily from stock sales and convertible notes. Operating cash flow used $16.8 million.

Material Changes vs. Prior Period

• Revenue: Remained negligible ($0 for Q3 2025 vs. $0 for Q3 2024; $39,990 for 9M 2025 vs. $63,000 for 9M 2024), derived solely from "right to try" humanitarian programs.
• Operating Expenses: Increased significantly to $6.9 million in Q3 2025 from $2.2 million in Q3 2024. The nine-month total rose to $44.6 million from $5.1 million.
• Share-Based Compensation: A major driver of expense, totaling $5.0 million in Q3 2025 and $26.0 million for the nine months, compared to $0 in the prior year periods. This reflects the recognition of RSU expenses following the March 2025 listing.
• Advisory Fees: $11.7 million recognized in the nine months ended Sept 30, 2025, primarily due to the listing fee earned by AFH Holdings and Advisory, LLC. No such fee was recorded in the prior year period.
• Net Loss: Net loss for the nine months increased to $46.6 million from $9.6 million in the prior year period.

Guidance, Outlook, Risks, and Unusual Items

Going Concern: The filing explicitly states substantial doubt regarding the company's ability to continue as a going concern. Cash on hand ($1.5 million) is insufficient to fund operations for the next 12 months. The company relies on additional financing, including an Equity Purchase Agreement with Mast Hill Fund and a Line of Credit with HCWG.

Unusual Items:

• Advisory Fee: A one-time fee of approximately $11.3 million was incurred upon the Nasdaq listing in March 2025.
• Derivative Liability: A loss of $380,162 was recognized due to the change in fair value of a derivative liability related to the equity line of credit discount.
• Convertible Notes: $4 million in convertible notes were issued in July 2025 with a 20% OID, maturing in November 2025 (extended).

Risks and Contingencies:

• Litigation: Outstanding litigation settlement payables of approximately $4.75 million (including $4.0 million to Orient EuroPharma and $600,000 to a vendor) remain unpaid as of September 30, 2025.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, citing material weaknesses in segregation of duties, related party transaction tracking, and IT user access.
• Regulatory: No products are approved for sale; commercialization depends on successful clinical trials and FDA approval.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $1.5 million cash balance against the $16.8 million operating cash burn rate for the nine-month period.
• Debt Maturity: Confirm the status of the $4.7 million convertible notes maturing in November 2025 and the company's ability to refinance or repay.
• Litigation Settlements: Assess the risk of default on the $4.75 million in unpaid litigation settlements and potential legal consequences.
• Internal Controls: Review the remediation plan for the material weaknesses in internal controls over financial reporting.
• Share-Based Compensation: Monitor the remaining unamortized stock-based compensation ($9.3 million) and its impact on future earnings.
• Equity Line Utilization: Track the utilization of the $50 million Equity Purchase Agreement with Mast Hill Fund as a primary funding source.